| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Serum Integrated Screen, Part 2 (NY)
Test Code16966
CPT Codes
81512<br /> <strong>For non-New York patient testing, use test code 16167</strong>
Includes
AFP, Unconjugated Estriol, hCG, Dimeric Inhibin A, *PAPP-A from Maternal Serum, Serum Integrated Screen, Part 1 and Interpretation
Preferred Specimen
3 mL serum
Minimum Volume
1 mL
Instructions
Collect between 14.0 weeks to 22 6/7 weeks.
Must complete patient demographic information using the "Maternal Serum Screen Requisition". Maternal date of birth (mm/dd/yy), estimated date of delivery by US/LMP/PE, weight, race, insulin-dependent diabetes status, repeat sample (Y/N), number of fetuses, and neural tube defect history must be provided for interpretation of results.
Must complete patient demographic information using the "Maternal Serum Screen Requisition". Maternal date of birth (mm/dd/yy), estimated date of delivery by US/LMP/PE, weight, race, insulin-dependent diabetes status, repeat sample (Y/N), number of fetuses, and neural tube defect history must be provided for interpretation of results.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 28 days
Refrigerated: 14 days
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Grossly lipemic
Methodology
Chemiluminescence (CL) • Immunoassay (IA)
FDA Status
PAPP-A: This test was performed using a kit that has not been cleared or approved by the FDA. The analytical performance characteristics of this test have been determined by Quest Diagnostics. This test should not be used for diagnosis without confirmation by other medically established means.
Setup Schedule
A.M. Sets up 6 days a week.
Limitations
Maternal age confirmation and number of fetuses may alter result interpretation. Maternal screening tests consistent with increased risk of trisomy should be confirmed with CVS or amniotic fluid specimen. Maternal serum screening yields a low percentage of false negatives. A wide range of other chromosomal abnormalities are not identified by maternal serum screening.
Clinical Significance
To assess maternal risk for carrying a fetus with Down Syndrome (Trisomy 21), Trisomy 18, or a neural tube defect. These types of tests are standard-of-care in obstetrics.
